KNBC-TV LA – Leronlimab Is a Promising Therapy for Severe to Critical Covid-19 Patients

Leronlimab is a novel humanized monoclonal antibody that is a CCR5 antagonist with the potential for multiple therapeutic indications, including a therapy for treating Covid-19 Patients.  Leronlimab targets and binds to the CCR5 receptor and, for example, inhibits RANTES (CCL5 found in high levels in severe to critical Covid-19 patients) from binding to CCR5 and thereby preventing the formation of chemokines and cytokines that cause the “cytokine storm” which invades the lungs causing severe inflammation and reductions in blood-oxygen levels. 

Cytodyn Inc., located in Vancouver, Washington, is a late-stage biotechnology company developing leronlimab.

CytoDyn’s Phase 2b/3 trial to evaluate the efficacy and safety of leronlimab for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study.  Patients are randomized to receive weekly doses of 700 mg leronlimab, or placebo. Leronlimab and placebo are administered via subcutaneous injection. The study has three phases: Screening Period, Treatment Period, and Follow-Up Period. The primary outcome measured in this study is: all-cause mortality at Day 28. Secondary outcomes measured are: (1) all-cause mortality at Day 14, (2) change in clinical status of subject at Day 14, (3) change in clinical status of subject at Day 28, and (4) change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.

On October 20, 2020, Cytodyn announced recommendations from the independent Data Safety Monitoring Committee (DSMC) following its review of the interim analysis of the Company’s Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19.  The interim analysis was performed on data from the first 195 (50%) of 390 planned patients.  The DSMC recommended that the trial continue without modification to achieve the primary endpoint and requests another interim analysis when enrollment reaches 75% level (or 293 patients) to review patient mortality and other clinical outcome data between the two study arms (leronlimab vs. placebo).


Discover Ting Cellular for Huge Savings Monthly

Use my referral link and each of us will get a $25 credit on our cell phone bill.  

Go -> Switch to TING and slash your cell phone bill!

My phone bill with Sprint averaged $155 per month for 2 smartphones–for over 10 years.  

With Ting my average bill is between $48 to $58 per month with 3 smart phones. I brought my own smartphones and easily ported my existing phone number to TING on the Sprint (CDMA) network having the same 4G LTE nationwide service for which I was previously paying Sprint $155 per month!

TING’s monthly price is $6 per phone per month plus usage (calling minutes, data, and sms/mms texts).  See the rates chart below.

You will have your choice of service on either the nationwide GSM network or on the nationwide CDMA network.  Your bill is from TING but your service will be place on either T-Mobile (GSM) or Verizon (CDMA) or Sprint (CDMA).

Ting automatically charges your credit card or check card for you monthly service.  

Here are TING’s monthly rates at $6 per phone plus usage:  

Use my referral link and each of us will get a $25 credit on our cell phone bill.  

See if your phone and number can be switched to TING!